Skip to main content

Equibles does not estimate personal net worth.

Get an email with a short summary when Iovance Biotherapeutics, Inc. publishes a filing, an earnings call transcript or a press release.

Get IOVA alerts

About Jim Ziegler

Geron Corp reported in an 8-K filed October 14, 2025 that Jim Ziegler resigned as Executive Vice President, Chief Commercial Officer, effective October 15, 2025. Iovance Biotherapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Iovance Biotherapeutics, Inc. includes Frederick G. Vogt, Ph.D. (CEO), Frederick Vogt (CEO and General Counsel), Corleen Roche (CFO) and 7 others.

“Effective October 15, 2025, Andrew J. Grethlein, Ph.D., Executive Vice President, Chief Operating Officer and Jim Ziegler, Executive Vice President, Chief Commercial Officer will depart from the Company.”
Geron Corp Form 8-K, filed October 14, 2025 · Read the filing

Affiliation history

Company network

Leadership on record at Iovance Biotherapeutics, Inc.

Recent activity